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Introduction: The combination of polyethylene glycol (PEG)ylated interferon (pegylated interferon) and ribavirin
has been shown to be an effective treatment for chronic hepatitis C virus. In general, common side effects related
to this combination therapy are mild and are well tolerated. However, peripheral neuropathy including
demyelinating polyneuropathy related to PEG-interferon α2a (pegylated interferon alfa-2a) is extremely rare. In the
literature, only one case of acute inflammatory demyelinating polyneuropathy related to PEG-interferon α2a has
been published previously.
Case presentation: To the best of our knowledge we present only the second case of acute inflammatory
demyelinating polyneuropathy related to PEG-interferon α2a, occurring in a 63-year-old Caucasian man. He
developed tingling, numbness, and weakness of his upper and lower extremities with acute neurological deficits
after five weeks of a combination therapy with PEG-interferon α2a and ribavirin for chronic hepatitis C virus
infection. His clinical course, neurological findings, and his electromyogram results were all consistent with acute
inflammatory demyelinating polyneuropathy. Our patient recovered completely after interferon was stopped and
symptomatic treatment and a further electromyogram showed a disappearance of neuropathy. Four weeks later,
PEG-interferon α2a was reintroduced with a gradually increasing dose without any reappearance of neurological
symptoms allowing hepatitis C seroconversion.
Conclusions: Recognition of this rare yet possible presentation is important for early and accurate diagnosis and
treatment. This case report also suggests that the reintroduction of PEGylated interferon in patients who had
presented with acute inflammatory demyelinating polyneuropathy related to interferon α may be safe, but this
must be confirmed by further studies.
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Interferon α (IFNα) has been widely used for the treat-
ment of chronic viral hepatitis. Overall, the common
side effects associated with this drug are well known.
The common side effects of IFN include flu-like symp-
toms, and psychiatric symptoms such as depression, sui-
cidal ideation, irritability, nervousness, and insomnia [1].
Less common side effects include hematopoietic sup-
pression, reversible hair loss, hearing loss, retinopathy,
dermatitis, seizures, and the development or exacerba-
tion of autoimmune diseases such as thyroid dysfunc-
tion, rheumatoid arthritis, sarcoidosis, systemic lupus
erythematosus, vitiligo, type 1 diabetes, and myasthenia
gravis [1]. Peripheral neuropathy is a rare and uncom-
mon side effect seen in patients treated with IFNα [2].
In recent years, a variety of peripheral neuropathies have
been reported in patients treated with IFN including
sensory neuropathy, autonomic neuropathy, Bell’s palsy,
and more recently, chronic inflammatory demyelinating
polyneuropathy (CIDP) [3]. To date, only one case of
acute inflammatory demyelinating polyneuropathy
(AIDP) related to polyethylene glycol (PEG)ylated inter-
feron alfa-2a (PEG-IFNα2a) has been published. To the
best of our knowledge, this is only the second case of se-
vere AIDP related to PEG-IFNα2a, which developed at
week five of IFNα2a therapy initiated for hepatitis C
virus infection and where the gradual reintroduction of
IFN was safe and without any residual neuromuscular
deficits.
Case presentation
A 63-year-old Caucasian man presented to our hospital
for chronic hepatitis C treatment. His initial physical
examination results were unremarkable. An initial liver
profile included aspartate aminotransferase (AST) 60IU/
mL, alanine aminotransferase (ALT) 74IU/mL, total bili-
rubin 1mg/dL, alkaline phosphatase 81IU/mL, albumin
5.2g/dL, and a prothrombin time (PT) of 76%. Serum
viral load was estimated to 3,545,770IU/mL (6.5log) with
a genotype 2a2c. The assessment of liver fibrosis by
FibroTestW and FibroScanW revealed a stage F2 of fibro-
sis. An abdominal ultrasound did not find any signs of
portal hypertension or cirrhosis. Upper gastrointestinal
endoscopy did not find any endoscopic signs of portal
hypertension. He was started on a course of treatment
comprising PEG-interferon α2a (PEGASYSW) 180μg sub-
cutaneously per week and ribavirin 800mg/day in
divided doses orally. A rapid virological response was
obtained after four weeks.
In the fifth week of treatment, he reported painful
paresthesia, tingling, numbness, and weakness of his
lower extremities. His neurological symptoms pro-
gressed rapidly over the course of one week to the point
of losing the ability to ambulate. In addition, our patientalso complained of tingling and numbness in the upper
extremities involving the fingers and wrists bilaterally.
PEGASYSW was discontinued due to an acute onset of
weakness of the upper and lower extremities. A neuro-
logical examination revealed normal cranial nerves with
normal bulk of muscles and tone; but weak muscle
strength in the upper extremities as well as in the hips,
knees, ankles and toes bilaterally. His tendon reflexes
were diminished significantly. A sensory examination
revealed decreased light touch, pinprick, and
temperature sensation from the feet to mid-calves as
well as hands, except for vibratory sense. A clinical diag-
nosis of acquired acute inflammatory demyelinating sen-
sorimotor polyneuropathy was made. Biochemical
screening tests, complete blood count, erythrocyte sedi-
mentation rate, anti-nuclear antibodies, serum cryo-
globulin level, human immunodeficiency virus (HIV)
test and cytomegalovirus (CMV) deoxyribonucleic acid
(DNA) were all normal. The results of an electromyo-
gram (EMG) revealed evidence of predominant motor
polyneuropathy with prominent demyelinating features,
including motor conduction block, low conduction vel-
ocity, and prolonged minimum F wave latency in the bi-
lateral ulnar, median, peroneal, and tibial nerves
(Table 1). Our patient recovered completely after one
month of stopping interferon (without stopping riba-
virin) and symptomatic treatment. His muscle weakness
and paresthesia were markedly improved, with normal
strength in all muscle groups; eventually he could walk
without difficulty. A further EMG showed a disappear-
ance of neuropathy. Four weeks later, IFN was reintro-
duced with a gradually increasing dose (90μg for two
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for the two remaining months) without reappearance of
neurological symptoms. He has not experienced relapse
and his neurological status remained stable. His viral
load of hepatitis C was negative at week 24 and six
months after stopping treatment. Currently our patient
is well and his neurological symptoms have resolved
completely with no residual neuromuscular deficits.
Discussion
The more probable etiologies of demyelinating polyneur-
opathy in our patient included infectious processes, tox-
ins and/or drugs, and immune mediated processes [4].
Viral infections such as hepatitis C virus (HCV), HIV
and CMV have been described to cause demyelinating
neuropathy [5]. Since polyneuropathy developed after
the negative conversion of HCV-ribonucleic acid (RNA)
transcript, and both HIV test and CMV DNA results
were negative in our patient, these were not the cause of
his neuropathy. Toxins and/or drugs are also common
etiologies for demyelinating neuropathies, which can be
acute or chronic in nature [4]. Common toxins/drugs
are barbital, sulfonamides, phenytoin, nitrofurantoin,
heavy metals, carbon monoxide, industrial poisons, and
certain drugs used for acquired immunodeficiency syn-
drome (AIDS) (zalcitabine, didanosine) [4]. Our patient
had no exposure to any of these toxins or drugs other
than PEGASYSW and ribavirin. Indeed, ribavirin has not
been associated with any type of reported neuropathy,
but PEGASYSW including IFNα has been implicated to
cause immune-mediated CIDP during chronic hepatitis
C treatment due to cytokine-induced apoptosis in the
myelin-producing oligodendrocytes, resulting in inhib-
ition of central nervous system remyelination [6]. The
timecourse for our patient’s symptoms was not long
enough to meet the criteria for a CIDP. The criteria for
CIDP usually include the clinical deterioration of neuro-
logical symptoms for a period greater than eight weeks,
as opposed to AIDP, which usually has deterioration
over a period of approximately four weeks or less as in
our patient’s case [7]. The pathogenesis of AIDP related
to PEGASYSW use is thought to be an acute immune-
mediated progress. The precise and exact immune regu-
latory function of IFNα including PEG-IFN is not well
understood, and it is likely similar to the mechanism
associated with IFN-induced CIDP described above
[3,8]. In addition, IFNα has been reported to enhance
in vivo and in vitro autoantibody production and may
upregulate transcription of genes associated with class I
major histocompatibility complex (MHC) antigens [9]. It
is likely that the levels of pro-inflammatory cytokines
may trigger autoimmune phenomena in immunologic-
ally predisposed individuals when IFN is administered.
Therefore, the immune system mistakenly attacks thehost’s nerve tissue after recognizing a molecular epitope
similar to a foreign antigen and this may result in acute
inflammatory neuropathy [10]. In addition, there have
been multiple reported cases of demyelinating neur-
opathy associated with cyroglobulinemia related to HCV
[11]. However, our patient had an undetectable cryo-
globulin level on multiple occasions, which rules out a
possibility of cryoglobulin-induced demyelinating neur-
opathy. Peripheral neuropathy related to PEGASYSW
improves after stopping treatment; some cases may re-
quire the use of corticosteroids, plasmapheresis or im-
munosuppressive drugs [12]. In our patient’s case his
symptomatology improved significantly four weeks after
stopping interferon and the use of a symptomatic treat-
ment. Four weeks later, IFN was reintroduced with a
gradually increasing dose without reappearance of his
neurological symptoms.
Conclusions
Acute inflammatory demyelinating neuropathy is a rare
complication of IFNα therapy. It is very important that
gastroenterologists and hepatologists recognize this rare
disorder for early diagnosis, management, and the pre-
vention of long-term neurological deficits. This case re-
port also suggests that the reintroduction of PEGylated
interferon may be safe, but this must be confirmed by
further studies.
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